• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT

    10/1/25 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email

    EXPAND is a prospective, blinded, multi-site clinical trial with diagnostic outcomes on all subjects

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients.

    Initiated in 2023, EXPAND is designed to be the defining prospective clinical trial in the category, supporting Natera's Fetal Focus™ single gene noninvasive prenatal test (NIPT) for inherited conditions. The study is differentiated by having all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing1, 2. EXPAND has enrolled a diverse, multi-ethnic population from leading academic medical centers and maternal fetal medicine clinics.

    Natera expects to report a large-scale analysis from the trial in the fourth quarter of 2025. This follows the successful initial readout of EXPAND earlier this year, in which Fetal Focus demonstrated 91% sensitivity and successfully identified 5/5 fetuses affected by challenging homozygous variants.

    Fetal Focus addresses a clear unmet need when the biological father is unavailable or unable to complete carrier testing. While testing both partners remains the guideline-recommended gold standard3,4 and the optimal approach to screen for affected pregnancies, if carrier testing of the biological father is not possible, Fetal Focus is a clinically useful alternative.

    "Fetal Focus is addressing an important clinical need for patients and has shown excellent performance in the initial readout of the EXPAND trial," said Sheetal Parmar, senior vice president of medical affairs, women's health at Natera. "Our proprietary LinkedSNP™ technology improves detection of inherited conditions, giving families and clinicians additional insights during pregnancy."

    References

    1. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results.
    2. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). https://clinicaltrials.gov/study/NCT06808880. Accessed July 2025.
    3. Gregg et al., Genetics in Medicine volume 23, pages 1793–1806 (2021).
    4. ACOG Practice Committee Opinion, 691 (2017; reaffirmed in 2025).

    About Natera

    Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

    Forward-Looking Statements

    All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251001833625/en/

    Investor Relations: Mike Brophy, CFO, Natera, Inc., [email protected]

    Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [email protected]

    Get the next $NTRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    9/22/2025$175.00Equal Weight
    Wells Fargo
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    2/20/2024$68.00 → $85.00Strong Buy → Outperform
    Raymond James
    12/29/2023$75.00 → $85.00Buy
    BTIG Research
    12/14/2023$70.00Buy
    Guggenheim
    More analyst ratings

    $NTRA
    SEC Filings

    View All

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    9/18/25 5:38:04 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    9/17/25 10:31:03 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.

    SCHEDULE 13G/A - Natera, Inc. (0001604821) (Subject)

    8/14/25 1:07:20 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT

    EXPAND is a prospective, blinded, multi-site clinical trial with diagnostic outcomes on all subjects Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients. Initiated in 2023, EXPAND is designed to be the defining prospective clinical trial in the category, supporting Natera's Fetal Focus™ single gene noninvasive prenatal test (NIPT) for inherited conditions. The study is differentiated by having all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing1, 2. EXPAND has enrolled

    10/1/25 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

    Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Clinical Oncology - Precision Oncology (JCO PO). The paper features results from a multi-institutional study evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker for patients with germ cell tumors (GCT), including testicular cancer. Testicular cancer represents approximately 95% of all GCTs1 and is the most common malignancy in men aged 15-35.2 Serum tumor markers (STM) play a central role in

    9/30/25 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

    Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer. Uterine cancer is the most common gynecologic malignancy in the United States.1 While most patients are diagnosed with early-stage disease and have a low risk of recurrence, many may have an up to 30% risk of recurrence despite uterine-confined disease.2

    9/29/25 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CO-FOUNDER Sheena Jonathan sold $2,514,354 worth of shares (14,070 units at $178.70), decreasing direct ownership by 1% to 239,182 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    9/22/25 8:05:06 PM ET
    $NTRA
    Medical Specialities
    Health Care

    EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $9,016,668 worth of shares (50,000 units at $180.33), decreasing direct ownership by 2% to 2,320,852 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    9/19/25 9:35:19 PM ET
    $NTRA
    Medical Specialities
    Health Care

    PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon gifted 300 shares, decreasing direct ownership by 0.25% to 120,559 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    9/17/25 8:05:04 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo resumed coverage on Natera with a new price target

    Wells Fargo resumed coverage of Natera with a rating of Equal Weight and set a new price target of $175.00

    9/22/25 8:32:15 AM ET
    $NTRA
    Medical Specialities
    Health Care

    RBC Capital Mkts initiated coverage on Natera with a new price target

    RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00

    3/13/25 8:17:14 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Barclays initiated coverage on Natera with a new price target

    Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00

    1/23/25 7:51:22 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Financials

    Live finance-specific insights

    View All

    Natera Reports Second Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4 million in the second quarter of 2024, an increase of 32.2%. Product revenues grew 32.3% over the same period. Generated a gross margin of 63.4% in the second quarter of 2025, compared to a gross margin of 58.8% in the second quarter of 2024. Processed approximately 853,100 tests in the second quarter of 2025, compared to approximately 760,300 tests in the second quarter of 2024, an increase of 12.

    8/7/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Report Its Second Quarter Results on August 7, 2025

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information   Event:   Natera's Second Quarter 2025 Financial Results Date:   August 7, 2025 Time:   1:30 p.m. PT (4:30 p.m. ET) Live Dial-In:   1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID:   7684785 Webcast:  

    7/31/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Reports First Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

    5/8/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

    Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

    6/5/23 11:06:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

    Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

    2/23/23 8:05:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

    AUSTIN, Texas, May 24, 2022  /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg

    5/24/22 8:03:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    6/7/24 12:07:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care